2024-03-29T09:58:29Z
https://u-ryukyu.repo.nii.ac.jp/oai
oai:u-ryukyu.repo.nii.ac.jp:02015603
2022-10-31T07:40:58Z
1642838163960:1642838198944:1642838199408:1642838222821
1642838403551:1642838412624
[原著]A Prospective Trial of Oral Betamethason and Oral Lorazepam in the Management of Delayed Nausea and Vomiting Induced by Cisplatin-Based Chemotherapy
Uehara, Tadashi
Yohena, Tomofumi
Kanematsu, Takanori
Teruya, Takao
Ikeda, Jiro
Okamoto, Junichi
Asoh, Hiroshi
Ichinose, Yukito
Betamethason
Chemotherapy
Cisplatm
Delayed emesis
Lorazepam
Lung Cancer
Purpose: The optimal treatment modality for delayed emesis occurring later than 24 hours after the administration of cisplatin-based chemotherapy has not yet been established. Patients and Methods: Twenty patients received 5-hydroxytryptamine 3 receptor antagonist intravenously for the treatment of acute emesis just before cisplatm infusion in the first cycle of treatment, and the thereafter they received oral administration of betamethason ($\2mgtimes3/day$) plus oral lorazepam ($\0.5mgtimes3/day$) for 5 days in trial I. In trial II, 14 patients who received the other anti-emetic regimen (methylprednisolone plus metoclopramide) for delayed emesis in the first cycle of chemotherapy were treated by this regimen for the second cycle of treatment. A complete response (CR) was defined as no emetic episodes and a partial response (PR) as no vomiting episodes but some nausea. The effects of anti-emetic treatments were evaluated for 5 days from the next day after cisplatin administration. Results: The mean control rate (percentage of CR+PR) and CR rate for delayed emesis for the 5-day period were 97% and 84%, respectively in trial I. The mean control rate in patients undergoing the other anti-emetic regimen in the first cycle of chemotherapy was 60% compared to 96% in the same patients undergoing this regimen in the second cycle of the same chemotherapy in trial II. Conclusions: Oral betamethason plus lorazepam demonstrated a high control rate for delayed nausea and vomiting induced by cisplatin-based chemotherapy.
論文
http://purl.org/coar/resource_type/c_6501
琉球医学会
Ryukyu Medical Association
2006
VoR
1346-888X
0289-1530
AN10369445
琉球医学会誌 = Ryukyu Medical Journal
1・2
25
22
17
eng
open access
琉球医学会